Last reviewed · How we verify

Bupivacaine 0.5% , Dexamethasone

Sisli Hamidiye Etfal Training and Research Hospital · FDA-approved active Small molecule

Bupivacaine blocks sodium channels to provide local anesthesia, while dexamethasone reduces inflammation and swelling at the injection site.

Bupivacaine blocks sodium channels to provide local anesthesia, while dexamethasone reduces inflammation and swelling at the injection site. Used for Regional anesthesia and nerve blocks, Perioperative pain management, Local infiltration anesthesia.

At a glance

Generic nameBupivacaine 0.5% , Dexamethasone
Also known asDekort, Marcaine 0,5 % Injectable Solution
SponsorSisli Hamidiye Etfal Training and Research Hospital
Drug classLocal anesthetic with corticosteroid adjuvant
TargetVoltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that inhibits sodium influx into nerve fibers, preventing depolarization and blocking pain signal transmission. Dexamethasone, a corticosteroid, suppresses inflammatory responses and reduces edema, potentially prolonging anesthetic duration and improving pain control. This combination is used for regional anesthesia and pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: